Canaccord raised the firm’s price target on Taysha Gene Therapies (TSHA) to $9 from $8 and keeps a Buy rating on the shares. The firm updated it model following Q1 results where the key takeaway was a “best case scenario” regulatory update for TSHA-102. The co has reached alignment + received written confirmation from the FDA on key elements of the pivotal Part B trial design in line with what the company had initially been targeting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies: Promising FDA Alignment and Strong Financials Justify Buy Rating
- Taysha Gene Therapies Advances in Rett Syndrome Trials
- Taysha Gene Therapies’ Positive Q1 2025 Earnings Call
- Positive Outlook for Taysha Gene Therapies: Expedited FDA Alignment and Strong Financial Position Support Buy Rating
- Taysha Gene Therapies reports Q1 EPS (8c) vs (10c) last year